NVO Stock Summary and Trading Ideas (Novo Nordisk A/S | NYSE:NVO)

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S trades on the NYSE stock market under the symbol NVO.

As of April 1, 2026, NVO stock price declined to $36.48 with 21,073,989 million shares trading.

NVO has a beta of 1.39, meaning it tends to be more sensitive to market movements. NVO has a correlation of 0.12 to the broad based SPY ETF.

NVO has a market cap of $162.09 billion. This is considered a Large Cap stock.

Last quarter Novo Nordisk A/S reported $12 billion in Revenue and $1.00 earnings per share. This beat revenue expectation by $255 million and exceeded earnings estimates by $.11.

In the last 3 years, NVO traded as high as $148.15 and as low as $35.12.

The top ETF exchange traded funds that NVO belongs to (by Net Assets): PVAL, PPH, AVDE, PID, WCMI.

NVO has underperformed the market in the last year with a return of -44.8%, while the SPY ETF gained +18.5%. In the last 3 month period, NVO fell short of the market, returning -25.8%, while SPY returned -3.6%. However, in the most recent 2 weeks NVO has outperformed the stock market by returning -1.8%, while SPY returned -2.1%.

NVO support price is $35.94 and resistance is $37.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVO shares will trade within this expected range on the day.